Literature DB >> 18425144

What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?

A Candoni, E Simeone, M Tiribelli, C Pipan, R Fanin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18425144     DOI： 10.1038/bmt.2008.98

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  4 in total

1.  Initial low-dose valganciclovir as a preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Katsuto Takenaka; Koji Nagafuji; Ken Takase; Tomohiko Kamimura; Yasuo Mori; Yoshikiyo Ito; Yukiko Nishi; Hideho Henzan; Koji Kato; Naoki Harada; Tetsuya Eto; Toshihiro Miyamoto; Takanori Teshima; Koichi Akashi
Journal:  Int J Hematol       Date:  2012-05-01       Impact factor: 2.490

Review 2.  Cytomegalovirus infection/disease after hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato
Journal:  Int J Hematol       Date:  2010-04-23       Impact factor: 2.490

3.  Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Katsuto Takenaka; Tetsuya Eto; Koji Nagafuji; Kenjiro Kamezaki; Yayoi Matsuo; Goichi Yoshimoto; Naoki Harada; Maki Yoshida; Hideho Henzan; Ken Takase; Toshihiro Miyamoto; Koichi Akashi; Mine Harada; Takanori Teshima
Journal:  Int J Hematol       Date:  2009-01-17       Impact factor: 2.490

4.  Improving safety of preemptive therapy with oral valganciclovir for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.

Authors:  Corinna Barkam; Haytham Kamal; Elke Dammann; Helmut Diedrich; Stefanie Buchholz; Matthias Eder; Jürgen Krauter; Arnold Ganser; Michael Stadler
Journal:  Bone Marrow Res       Date:  2012-12-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.